7 results about "Mannan-binding lectin" patented technology

The invention discloses a marker combination, a kit thereof and application of the marker combination to prediction of diabetic peripheral neuropathy, the marker combination comprises human angiotensin (ANG), human vascular endothelial cell adhesion molecule 1 (VCAM1) and human mannan binding lectin serine peptide 1 (MASP1), TMT quantitative proteomics and PRM targeted proteomics are adopted, and the marker combination is used for detecting diabetic peripheral neuropathy. A technology combination strategy of an ELISA experiment is adopted, and key differential expression proteins such as MASP1, VCAM1 and ANG in serum exosomes of patients with diabetic peripheral neuropathy are systematically screened and verified. By establishing a multi-model machine learning diagnosis system based on logistic regression, a support vector machine and a naive Bayes algorithm, simple and rapid identification of diabetic peripheral neuropathy patients is realized, and a new experimental basis is provided for clarification of a molecular regulation network of diabetic peripheral neuropathy; more importantly, a rapid screening tool with clinical application potential is developed.

The present disclosure provides synthetic compositions useful as inhibitors of mannan-binding lectin-associated serine protease-2 (MASP-2), including compositions that selectively inhibit MASP-2 over thrombin, as well as methods for their production and use.

The present invention provides a double-stranded RNA used to suppress the expression of mannan-binding lectin-related serine protease 2 (MASP2) in cells, cells containing the nucleotide encoding the same, and a method for treating a disease or condition mediated by or related to MASP2 expression in a subject using the dsRNA or cells.

Provided are a double-stranded RNA for inhibiting the expression of mannan-binding lectin-associated serine protease 2 (MASP2) in a cell, a cell comprising a nucleotide encoding the same, and a method of using the dsRNA or cell to treat a disease or condition mediated or associated with the expression of MASP2 in a subject.

The present invention relates to compounds of formula (I) as inhibitors of mannan-binding lectin-associated serine protease-2 (MASP-2), including inhibitors that selectively inhibit MASP-2 over thrombin, for use in the treatment of e.g. a thrombotic microangiopathy (TMA), a renal condition, an inflammatory reaction resulting from tissue or organ transplantation, an ischemia reperfusion injury, a complication associated with diabetes, a cardiovascular disease or disorder, an inflammatory gastrointestinal disorder, a pulmonary disorder, an ophthalmic disease or disorder, disseminated intravascular coagulation, graft-versus-host disease, veno-occlusive disease, diffuse alveolar hemorrhage, idiopathic pneumonia syndrome, capillary leak syndrome, engraftment syndrome, fluid overload, a traumatic brain injury (TBI) or a combination thereof